Evaluation of the usefulness and safety of goserelin plus tamoxifen as neoadjuvant hormone therapy for premenopausal patients with hormone receptor-positive breast cancer
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000003700
- Lead Sponsor
- St. Luke's International Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 55
Not provided
(1) Patients with previous treatment for the breast cancer. (2) Patients receiving drugs having a potential influence on the status of sex hormones (hormone replacement therapy, raloxifene, etc.). (However, patients after washout for at least 2 months can be enrolled.) (3) Patients with myocardial infarction or congestive heart failure at the past history, or patients who need treatment of ischemic hear disease, arryhythmia or valvular disorder. (4) Patients with active double cancer. (5) Inflammatory breast cancer (6) Synchronous or asynchrous bilateral breast cancer. (7) Allergy for radio-enhancer (8) New test drug (9) Severe psychosomatic disease (10) Patients whom doctors judged inadequate to the enrollment of this study by other reasons.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical response
- Secondary Outcome Measures
Name Time Method Pathological response Safety Clinical usefulness Changing of Ki67-score Disease Free Survival